Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Equillium Announces $35 Million Financing with RA Capital Management
08:00am, Friday, 13'th Mar 2026
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA,
Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
05:24pm, Wednesday, 25'th Feb 2026
Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
08:30am, Wednesday, 25'th Feb 2026
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today anno
Short Interest in Equillium, Inc. (NASDAQ:EQ) Increases By 32.2%
04:35am, Wednesday, 04'th Feb 2026
Equillium, Inc. (NASDAQ: EQ - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 1,473,443 shares, a
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Feb 2026
LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today anno
Equillium to Participate in Upcoming Investor Conferences
04:35pm, Thursday, 20'th Nov 2025
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
04:05pm, Thursday, 13'th Nov 2025
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR
Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript
06:21pm, Wednesday, 05'th Nov 2025
Equillium, Inc. ( EQ ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases November 5, 2025 12:00 PM EST Company Participants Bruce Steel - Co-Founder, C
Equillium to Participate in Upcoming Investor Conferences
08:30am, Tuesday, 04'th Nov 2025
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Nov 2025
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today anno
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
08:00am, Wednesday, 22'nd Oct 2025
Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis Virtual webinar to feat
Equillium Announces Leadership and Corporate Updates
04:02pm, Monday, 06'th Oct 2025
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
05:30am, Tuesday, 23'rd Sep 2025
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neur
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 03'rd Sep 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
07:30am, Wednesday, 03'rd Sep 2025
While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing
